Provided By PR Newswire
Last update: Mar 7, 2024
-- New weight loss drugs like Ozempic, Wegovy and Zepbound
may make oral birth control pills less effective at certain points --
SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.
Read more at prnewswire.com1.19
-0.01 (-0.83%)
Find more stocks in the Stock Screener
The trading volume of these stocks is deviating from the norm in today's session.
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.